The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (regranex): A core model with an application using swedish cost data

Value in Health

Volumn 3, Issue SUPPL. 1, 2000, Pages 39-46

  Persson, Ulf ^a   Willis, Michael ^a   Ödegaard, Knut ^a   Apelqvist, Jan ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Diabetic foot ulcer; Model

Indexed keywords

ANTIBIOTIC AGENT; BECAPLERMIN; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DRUG COST; DRUG EFFICACY; FOLLOW UP; FOOT ULCER; GANGRENE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SWEDEN; TREATMENT OUTCOME; ULCER HEALING; WOUND CARE;

EID: 0034505166     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.36027.x     Document Type: Article

References (17)

1. Economic Aspects of Diabetic Neuropathy and Related Diabetic Complications
2. The economic cost of non-insulin dependent diabetes mellitus
3. The burden of diabetic foot ulcers
4. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting
5. Cost-effective management of diabetic foot ulcers: A review
6. The Pros and Cons of Modelling in Economic Evaluation
7. Markov models in medical decision-making: A practical guide
8. The cost of illness of patients with diabetic foot ulcers
9. The dysvascular foot: A system for diagnosis and treatment
10. Topical treatment of diabetic foot ulcers: An economic analysis of treatment alternatives and strategies
11. Diabetic foot ulcers in a multidisciplinary analysis of primary healing and healing with amputation
12. Efficacy and safety of becaplermin in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies